- Home
- CDTG vs RLYB Comparison
CDTG vs RLYB Comparison
Compare CDTG & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTG
- RLYB
- Stock Information
- Founded
- CDTG 2012
- RLYB 2018
- Country
- CDTG China
- RLYB United States
- Employees
- CDTG N/A
- RLYB N/A
- Industry
- CDTG
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- CDTG
- RLYB Health Care
- Exchange
- CDTG NYSE
- RLYB Nasdaq
- Market Cap
- CDTG 24.5M
- RLYB 25.0M
- IPO Year
- CDTG 2024
- RLYB 2021
- Fundamental
- Price
- CDTG $2.45
- RLYB $0.25
- Analyst Decision
- CDTG
- RLYB Hold
- Analyst Count
- CDTG 0
- RLYB 5
- Target Price
- CDTG N/A
- RLYB $11.50
- AVG Volume (30 Days)
- CDTG 362.2K
- RLYB 194.2K
- Earning Date
- CDTG 04-29-2025
- RLYB 05-08-2025
- Dividend Yield
- CDTG N/A
- RLYB N/A
- EPS Growth
- CDTG N/A
- RLYB N/A
- EPS
- CDTG 0.72
- RLYB N/A
- Revenue
- CDTG $31,432,824.00
- RLYB $636,000.00
- Revenue This Year
- CDTG N/A
- RLYB N/A
- Revenue Next Year
- CDTG N/A
- RLYB N/A
- P/E Ratio
- CDTG $3.40
- RLYB N/A
- Revenue Growth
- CDTG N/A
- RLYB N/A
- 52 Week Low
- CDTG $1.16
- RLYB $0.22
- 52 Week High
- CDTG $4.64
- RLYB $2.00
- Technical
- Relative Strength Index (RSI)
- CDTG N/A
- RLYB 22.80
- Support Level
- CDTG N/A
- RLYB $0.24
- Resistance Level
- CDTG N/A
- RLYB $0.28
- Average True Range (ATR)
- CDTG 0.00
- RLYB 0.06
- MACD
- CDTG 0.00
- RLYB -0.02
- Stochastic Oscillator
- CDTG 0.00
- RLYB 6.12
About CDTG CDT ENVIRONMENTAL TECH INV HLDG LTD
CDT Environmental Technology Investment Holdings Ltd is a waste treatment company. The company generates revenue through the design, development, manufacture, sales, installation, operation and maintenance of sewage treatment systems and by providing sewage treatment services. It engages in two business lines namely, rural sewage treatment and septic tank treatment in both urban and rural areas.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.